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Abstract
Background: A study carried out in 2003–2005 in Southern Benin showed a day-28 sulphadoxine-
pyrimethamine (SP) monotherapy failure rate greater than 40%, while for SP combined with
artesunate (SP-AS) the failure rate was 5.3%. Such a large difference could be explained by the
relatively short 28-day follow-up period, with a substantial number of recurrent infections possibly
occurring after day 28. This paper reports the treatment outcome observed in the same study
cohort beyond the initial 28-day follow-up.
Methods: After the 28-day follow-up, children treated with either chloroquine alone (CQ), SP or
SP-AS, were visited at home twice a week until day 90 after treatment. A blood sample was
collected if the child had fever (axillary temperature ≥37.5°C). Total clinical failure for each
treatment group was estimated by combining all the early treatment failures and late clinical failures
that occurred over the whole follow-up period, i.e. from day 0 up to day 90. Pre-treatment
randomly selected blood samples were genotyped for the dhfr gene (59) and the dhps gene (437
and 540) point mutations related to SP resistance.
Results: The PCR-corrected clinical failure at day 90 was significantly lower in the SP-AS group
(SP-AS: 2.7%, SP alone: 38.2%; CQ: 41.1%) (Log-Rank p < 0,001). The most prevalent haplotype
was dhfr Arg-59 with the dhps Gly-437 mutant and the dhps 540 wild type (85.5%). The dhps 540
mutation could be found in only three (8.3%) samples.
Conclusion: Combining artesunate to SP dramatically increased the treatment efficacy, even when
extending the follow-up to day 90 post-treatment, and despite the high percentage of failures
following treatment with SP alone. Such a good performance may be explained by the low
prevalence of the dhps 540 mutation, by the rapid parasite clearance with artesunate and by the
level of acquired immunity.
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Background
In Benin, the current national anti-malarial drug policy
was established in 2004 and selected two artemisinin-
based combination therapies (ACT), artemether-lumefan-
trine (AL) and amodiaquine-artesunate (AQAS) as the
first- and second-line treatment, respectively [1,2]. This
change was needed given the high resistance to chloro-
quine (CQ), the first-line treatment for many years and
the variable treatment efficacy of sulphadoxine-pyrimeth-
amine (SP), the second-line treatment [3]. Indeed, though
not widely used, SP treatment failure (28-day PCR uncor-
rected) varied from 3.3% in the north to 45.9% in Central
Benin and 14.3% at the coast [3].
In Africa, SP treatment failure is strongly related to the
combination of 3 mutations in the dihydrofolate reduct-
ase (dhfr) gene (Asn-108 + Ile-51 + Arg-59) with 2 (Gly-
437 + Glu-540) in the dihydropteroate synthetase(dhps)
gene [4,5]. The dhfr mutations are selected in a stepwise
manner, with the Asn-108 mutation occurring first, fol-
lowed by the Ile-51 and then the Arg-59 mutations. There-
fore, the Arg-59 mutation is considered as a surrogate
marker for the dhfr triple mutation [5].
The use of ACT is expected to improve the therapeutic effi-
cacy of the treatment and also prevent the emergence and
spread of Plasmodium falciparum drug resistance [6,7].
Though there is general consensus on the use of ACT, it is
less clear which specific ACT should be chosen by a given
country and on what criteria. It is often stated that the
partner drug to the artemisinin derivative should also be
efficacious and a lower-than-expected efficacy of an ACT
has been observed where there was a substantial resistance
to the partner drug [8,9]. However, in Thailand the com-
bination mefloquine-artesunate was implemented at a
time when resistance to mefloquine was extremely high
[10] and this halted the progression of mefloquine resist-
ance [11]. This may not apply to sub-Saharan Africa where
the intensity of transmission is higher than in South-East
Asia and could increase the probability of selecting resist-
ant parasites to the partner drug during the period when
the artemisinin derivative has already been eliminated.
Furthermore, considering that a three-day dosing period
with an artemisinin derivative is inadequate, it is more
likely that when the partner drug is not effective, there
would be a high number of therapeutic failures. There-
fore, combining artesunate (AS) to sulphadoxine-
pyrimethamine (SP) should only marginally improve the
treatment efficacy where SP resistance is widespread.
However, this is not what was observed in a study carried
out in Benin in 2003, before the change of the anti-malar-
ial drug policy, that tested both CQ and SP, the first and
second-line treatment, and SP combined to AS as a poten-
tial alternative treatment. The treatment failure at day 28
with SP alone was above 40%, while that of SP combined
with AS was only 5.3% [12]. Such large difference could
have been dependant on the relatively short 28-day fol-
low-up period and it was suspected that substantial recru-
descence rates would occur after day 28. Therefore,
follow-up was extended until day 90 after treatment and
pre-treatment parasites were genotyped for molecular
markers related to SP resistance. The results are reported
below.
Methods
Study site and population
The study site and the population have already been
described elsewhere [12]. Briefly, the study was carried out
in three adjacent peri-urban sites in the coastal lagoon
near Cotonou, where malaria is hyper-endemic [13-15]. A
census of all residents was carried out before the clinical
trial and a list of 6–59 month old children was produced
[12]. After having obtained the parents' and/or the guard-
ians' written informed consent, a cohort of 556 children
was established by randomly selecting them from the cen-
sus database.
Study design and procedure
Between July 2003 and January 2005, children in the
cohort were visited at home twice a week, had their axil-
lary temperature checked and if it was found equal or
above 37.5°C, a blood sample for microscopic examina-
tion (thick and thin blood film) and for later genotyping
was collected. Similar procedures were carried out when
children of the cohort attended the health facilities within
the study area. Children with fever (axillary temperature
≥37.5°C), a P. falciparum mono-infection, with a parasite
density between 1,000–200,000/μL, a PCV≥15% and
without severe malaria [16], danger signs (prostration,
inability to drink, recent convulsion, persistent vomiting),
other concomitant illness or underlying disease were
included in the clinical trial and allocated according to a
predefined randomization list to either CQ (25 mg/kg
over three days), SP (25 mg/kg of sulphadoxine and 1.25
mg/kg of pyrimethamine in a single dose) or SP-AS (SP:
25 mg/kg of sulphadoxine and 1.25 mg/kg of pyrimeth-
amine in a single dose, and AS: 12 mg/kg/over three days).
Children were observed for at least 1 hour after treatment;
if vomiting occurred within 30 minutes, a full dose of
treatment was administered, half dose if it occurred
between 30 minutes and 1 hour. Allocation to treatment
groups was blinded (sealed opaque envelopes) until final
recruitment of the patient.
Patients follow-up and outcome measurements
Besides the first three days of treatment (days 0, 1 and 2),
children were seen at scheduled visits at days three, seven,
14, 21 and 28 [17]. The 28-day follow-up outcomes were
defined according to the standard WHO classification:
early treatment failure (ETF), late clinical failure (LCF),Malaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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late parasitological failure (LPF) and adequate clinical and
parasitological response (ACPR) [17]. All clinical failures
detected beyond day 28 were defined as LCF. After having
completed the standard 28-day follow-up, all children
with either ACPR or LPF were visited at home twice a week
up to day 90 in order to detect all possible clinical malaria
attacks. During these post 28-day follow-up visits, a phy-
sician examined the child and the body temperature was
checked. If the child had fever (axillary temperature
≥37.5°C), a thick blood film for detecting peripheral par-
asitaemia was done and a blood sample was collected on
filter paper for later genotyping. Moreover, parents/legal
guardians were encouraged to attend the research collab-
orative health centres whenever the child was sick. Qui-
nine (24–30 mg/kg/day for seven days) was used as rescue
treatment and administered to all children with ETF or
LCF. Rescue treatment was also given to children with per-
sistent vomiting following the administration of one of
the study drugs. Children with an LPF were followed up
and treated only if they developed clinical malaria. All
treatments were given under direct observation.
Laboratory methods
Parasite count and haematotological assays
Thin blood films were fixed with methanol and were
stained, together with thick films, with Giemsa 10% for
10 minutes. Parasite density was determined according to
the number of parasites per 200 white blood cells (WBC),
and assuming a total WBC count of 8,000/μl. If gameto-
cytes were seen, the gametocyte count was extended to
1,000 WBC. Slide reading was blinded to patients' identity
and treatment allocation. Packed cell volume (PCV),
measured by micro-haematocrit centrifugation, was
assessed at day 0, 14 and 28.
Parasite genotyping
Parasite genotyping was done at day 0 and the day of
recurrent parasitaemia from blood collected and dried on
filter paper (Whatman filter paper grade 3). DNA was
purified and genotyping done by nested PCR for variable
blocks within the merozoite surface protein 1 and 2
(msp1 and msp2) as described previously [18,19]. A
recrudescence was defined when at least one common
band was observed for both markers in the day 0 sample
and at the day of recurrent parasitaemia. A new infection
was defined when no common band was observed for at
least one of the two markers between day 0 and the day of
recurrent parasitaemia. Patients with a recurrent infection
identified as new were considered as ACPR for the PCR-
corrected estimate.
Mutations related to SP resistance
Only children having received either SP or SP-AS were
included in this analysis. Patients in the CQ group were
excluded since the objective was to estimate the preva-
lence of molecular markers related to SP resistance and
explain the high efficacy in the SP-AS arm. Patients classi-
fied as ETF were also excluded because of the previously
reported lack of association between SP resistance molec-
ular markers and ETFs [4,5].
Genotyping was done on blood samples collected before
treatment at day 0 in all patients with recurrent parasitae-
mia and in about half of randomly selected patients hav-
ing had ACPR between day 0 to 28. Considering the
stepwise selection of the triple mutation, one point muta-
tion for the dhfr gene (59), and two for the dhps gene (437
and 540) were analysed. Genotyping was carried out by
mutation-specific nested polymerase chain reaction
(PCR) and/or restriction digestions as described elsewhere
[20]. Each dhfr and dhps codon was characterized as wild-
type (no mutation present), mixed (both wild and mutant
genotypes in the same infection), or pure mutant (only
mutant genotypes detected).
Statistical analysis
The follow-up time after day 28 was arbitrarily fixed at day
90 after the initial treatment. However, between day 29
and 90, blood slides were done only on children with
fever so that only LCF but not LPF could be identified.
Therefore, in order to make the first (day 0 to 28) and the
second (day 29 to 90) follow-up periods comparable,
only children experiencing either ETF or LCF between day
0 and day 90 were considered as clinical treatment fail-
ures; total clinical failure (TCF), for each treatment group
was estimated by combining all the ETF and LCF that
occurred over the whole follow-up period, i.e. from day 0
up to day 90. In addition, the risk of evolving towards a
clinical episode was estimated for the children who dur-
ing the first 28-day follow-up experienced a LPF identified
as a recrudescence by PCR genotyping.
Concerning the dhfr/dhps  mutations, infections were
defined as wild type when no mutation could be detected,
single mutant when only the dhfr 59 mutation was
present, double mutant when the dhfr 59 mutation was
present with either the dhps 437 or the 540 mutations, and
triple mutant when all three mutations were detected.
Data analysis
Data were analysed with STATA version 10 (Stata Corpo-
ration, College Station, Texas, US). Descriptive statistics
were used to summarize baseline values and demography
data. Data not normally distributed were compared by
Wilcoxon Rank sum test or Kruskal-Wallis analysis of var-
iance. Categorical data were compared using the chi-
square or the Fisher's exact test when required. The risk of
clinical failure was estimated both by Per Protocol and Kap-
lan Meier survival analysis at 42, 63 and 90 day. In the
Kaplan Meier survival analysis, each patient contributedMalaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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to the analysis for the time s/he was followed up. When
estimating TCF, data were censored for subjects who
ended follow-up prior to day 90 and for new P. falciparum
(PCR corrected) infections. In the survival analysis, clini-
cal failure risks were described by Kaplan Meier estimates
and compared between groups with a log-rank test. A p-
value p < 0.05 was considered as statistically significant.
Pair-wise comparisons of treatment efficacy at day 90 were
made with a Cox proportional hazards model.
Ethical approval
The study was approved by the Minister of Health of
Benin, the Ethical Committee of the Faculté des Sciences
de la Santé, Cotonou, Benin and by the Ethical Commit-
tee of the Institute of Tropical Medicine, Antwerp. Written
informed consent was obtained from all children's par-
ents or guardians.
Results
Extended follow-up until 90 days after treatment
The baseline characteristics by treatment group and the
treatment efficacy at day 28 post-treatment have already
been published [12]. However, it should be noted that
estimates of the treatment failure in the current analysis
are different (lower) from the previous one as only ETF
and LCF, but not LPF, were considered as treatment fail-
ures in order to harmonize the first 28-day follow-up and
the second one from day 29 to 90. From the initial cohort
of 556 children under surveillance, 237 (42.6%) children
were included in the trial and randomized to one of the
three study treatments. Twenty-two children (9%) did not
complete the 28-day follow-up (11 withdrew consent; five
moved out of study area, and six took different anti-malar-
ials). By day 28, 54 clinical treatment failures (34 ETF and
20 LCF) received the rescue treatment. Between day 29
and 90, six additional children (three in the SP-AS and
three in the SP arm) were lost to follow-up and 19 addi-
tional LCF (PCR uncorrected) were identified: four
between day 29 and 42 (CQ: 2, SP: 1, and SP-AS: 1), four
between day 43 and 63 (CQ: 1, and SP-AS: 3) and 11
between day 64 and 90 (CQ: 2, SP: 4, and SP-AS: 5) (Fig-
ure 1). Thus, in the Per Protocol analysis, TCF (PCR uncor-
rected) at day 90 was 13.7% (10/73) in the SP-AS, 44.6%
(29/65) in the SP alone, and 47.9% (34/71) in the CQ
group. After PCR correction, these rates were 2.7% (2/73),
41.5% (27/65) and 42.3% (30/71), respectively (Table 1).
TCF rates estimated by Kaplan-Meier survival analysis
(PCR-corrected) were similar to the PP analysis, i.e. SP-AS
2.7%, SP alone 38.2%, CQ 41.1% (Figure 2). Differences
between monotherapy groups and SP-AS were highly sig-
nificant (Log-Rank p < 0,001) and the hazard of clinical
failure estimated by Cox regression both for CQ and SP
were significantly higher compared to SP-AS (CQ: HR =
20.4; p < 0.001. SP alone: HR = 18.2, p < 0.001).
Dhfr and dhps mutations and therapeutic response
DNA could be amplified for the majority of blood sam-
ples (63/65) and one additional sample was not interpret-
able after genotyping. The prevalence of the dhfr 59 and
dhps 437 mutations (pure or mixed) was high, both in the
SP alone (dhfr 59: 97.2%; dhps 437: 88.9%) and in the SP-
AS (dhfr 59: 88.5%; dhps 437: 96.2%) groups (Table 2). In
contrast, the prevalence of the dhps 540 mutation was low
in the SP group (8.3%) while no mutation was found in
Table 1: TCF (ETF+LCF) between day 28 and day 90 by treatment group
TCF at different day post-treatment CQ SP SP – AS
Day 28: patients analysed 71 68 76
TCF n (%) uncorrected: 29 (40.8) 24 (35.3) 1 (1.3)
TCF, PCR corrected: 29 (40.8) 24 (35.3) 1 (1.3)
Day 42: 71 68 75
TCF n (%) uncorrected: 31 (43.7) 25 (36.8) 2 (2.7)
TCF, PCR corrected: 30 (42.2) 25 (36.8) 1 (1.4)
Day 63 71 66 73
TCF n (%) uncorrected: 32 (45.1) 25 (37.9) 5 (6.8)
TCF, PCR corrected: 30 (42.2) 25 (37.9) 2 (2.7)
Day 90 71 65 73
TCF n (%) uncorrected: 34 (47.9) 29 (44.6) 10 (13.7)
TCF, PCR corrected: 30 (42.3) 27 (41.5) 2 (2.7)Malaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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Trial profile (90 day follow-up) Figure 1
Trial profile (90 day follow-up). LCF: late clinical failure. ETF: early treatment failure. CQ: Chloroquine; SP: Sulphadoxine-
Pyrimethamine; AS: Artesunate. LFU: Lost to follow-up; FU: Follow-up.
Note: ETF and LCF were not corrected by PCR
237 children randomized
79 CQ 77 SP 81 SP-AS
68 completed 28 days FU
16 ETF 8 LCF
76 completed 28 days FU
0E T F 1L C F
75 completed 42 days FU
1L C F
71 completed 28 days FU
18 ETF 11 LCF
71 completed 42 days FU
2L C F
68 completed 42 days FU
1L C F
73 completed 63 days FU
3L C F
71 completed 63 days FU
1L C F
66 completed 63 days FU
2L F U
1L F U
73 completed 90 days FU
5L C F
71 completed 90 days FU
2L C F
65 completed 90 days FU
4L C F
1L F U
8L F U 9L F U 5L F U
2L F UMalaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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Kaplan Meier survival curves by treatment groups and PCR correction until day 90 post-treatment Figure 2
Kaplan Meier survival curves by treatment groups and PCR correction until day 90 post-treatment. A. PCR non-
corrected. B. PCR corrected.
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Table 2: Individual dhfr and dhps mutations by treatment and treatment outcome
Total
SP
SP Total
SP-AS
SP-AS Total
Treatment success Treatment failure Treatment success Treatment failure
N = 38# N = 24# N = 14 N = 27* N = 23* N = 4 N = 65#*
dhfr n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Arg-59
Wild 1 (2.8) 1 (4.5) 0 (0) 3 (11.5) 2 (9.1) 1 (25) 4 (6.5)
Mutant 25 (69.4) 16 (72.7) 9 (64.3) 18 (69.2) 15 (68.2) 3 (75) 43 (69.4)
Mixed 10 (27.8) 5 (22.7) 5 (35.7) 5 (19.2) 5 (22.7) 0 (0) 15 (24.2)
dhps
Gly-437
Wild 4 (11.1) 2 (9.1) 2 (14.3) 1 (3.8) 1(4.5) 0 (0) 5 (8.1)
Mutant 30 (83.3) 19 (86.4) 11 (78.6) 24 (92.3) 20 (90.9) 4 (100) 54 (87.1)
Mixed 2 (5.6) 1 (4.5) 1 (7.1) 1 (3.8) 1(4.5) 0 (0) 3 (4.8)
Glu-540
Wild 33 (91.7) 21 (95.5) 12 (85.7) 26 (100) 22 (100) 4 (100) 59 (95.2)
Mutant 3 (8.3) 1 (4.5) 2 (14.3) 0 (0) 0 (0) 0 (0) 3 (4.8)
Mixed 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
# 1 not amplified and 1 not interpretable; *1 not amplified
Table 3: Parasite haplotypes and treatment outcome by treatment group
Haplotype SP SP-AS Total
dhfr59-dhps437-dhps540 Success Failure Success Failure
n (%) n (%) n (%) n (%) n (%)
M-M-W 19 (86.4) 12 (85.7) 19 (86.4) 3 (75.0) 53 (85.5)
M-W-M 1 (4.5) 2 (14.3) 0 (0) 0 (0) 3 (4.8)
M-W-W 1 (4.5) 0 (0) 1 (4.5) 0 (0) 2 (3.2)
W-M-W 1 (4.5) 0 (0) 2 (9.1) 1 (25.0) 4 (6.5)
M: Mutant; W: WildMalaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
Page 8 of 12
(page number not for citation purposes)
the SP-AS group. In both treatment groups, no significant
association between any individual mutation and treat-
ment outcome was found. Even though the haplotype
59M437M540W (Arg-59 + Gly-437 + Glu-540) (85.5%)
was the most represented, it was not associated to treat-
ment failure (p = 1.0) (Table 3).
Long term risk of clinical malaria among LPF and ACPR 
identified by day 28
By the Day 28, 38 children experienced a LPF confirmed
to be a recrudescence by PCR genotyping (CQ: 25, SP: 10,
and SP-AS: 3) [12]. Among these 38 LPF, 11 (28.9%)
evolved towards LCF after an average of 15.4 days
(95%CI: 7.9–22.9), 8 (72.7%) of them were classified as
recrudescence: seven (CQ: 3 and SP: 4) before day 28 and
an additional patient in the SP-AS group between day 29
and day 90 (Table 4). The 3 (27.3%) remaining LPF
Table 4: Clinical failures (CF) by day 42, 63 and 90 post-treatment, by clinical outcome at day 28 and treatment group
Outcome at D28° Treatment group
(N)
CF Total CF
D29-90
D7-28 D29-42 D43-63 D64-90
ACPR
(n = 123)
SP-AS R 0 000 0
6 8 N 0 025 7
CQ R 0 100 1
1 8 N 0 100 1
SP3 7 R 0 102 3
3 7 N 0 001 1
LPF new infection
(n = 7)
SP-AS R 0 000 0
4 N 0 100 1
CQ R 0 000 0
2 N 0 000 0
SP R 0 000 0
1 N 0 001 1
LPF recrudescence
(n = 38)
SP-AS R 0 010 1
3 N 0 000 0
CQ R 3 000 3
2 5 N 0 012 3
SP R 4 000 4
1 0 N 0 000 0
°ACPR: Adequate Clinical and Parasitological Response;
LPF: Late Parasitological Failure; R = recrudescence; N = new infection; D = day).Malaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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patients having evolved towards LCF and classified as new
infections (1 by day 63 and 2 by day 90) were all in the
CQ group. In the SP group, among the 10 children classi-
fied as LPF, the 4 (40%) having evolved towards clinical
failure had a mean age of 26 months (95%CI: 16.9–35.1)
while this was 37.7 months (95%CI: 25.7; 49.6) for those
without LCF. No gametocyte was detected in LPF patients.
Among the 7 patients with LPF by day 28 and classified as
new infection by genotyping (in the estimation of treat-
ment outcome considered as ACPR), 2 evolved towards
LCF (SP-AS: 1, before day 42; SP: 1, before day 90) (Table
4). Among the remaining 123 ACPR patients (parasite-
free by day 28), 13 (10.6%) evolved towards LCF (9 new
infections and 4 recrudescences) (Table 4). Overall, the
proportion of ACPR (including the LPF new infections)
who evolved toward LCF was significantly lower than in
the LPF group (p = 0.009). In 2 (1.5%) (SP-AS: 1, and SP:
1) of the 130 ACPR (123 parasite free and 7 new infection
children by day 28) gametocytes appeared after day 28.
Between day 29 and day 90, no fever was detected in the
majority of children with either LPF or ACPR by day 28,
so that no blood slide was taken.
Discussion
In this area, combining AS to SP dramatically increased
the treatment efficacy despite evidence of a high treatment
failure at day 28 in children treated with SP alone [12].
Such a good performance of the combination could have
been due to the duration of the follow-up period, not long
enough to capture all failures. Indeed, it has been stated
that a 42-day follow-up can capture almost all failures
after treatment with anti-malarial drugs that have a termi-
nal half-life of less than one week and that the traditional
28-day follow-up may underestimate the true failure rate
by as much as 40% [21]. However, these conclusions were
based on trials carried out in low transmission areas, as
there were no data with a follow-up longer than 28 days
in higher transmission settings [21]. In this study, the fol-
low-up was extended up to 90 days after treatment,
though failures were identified passively so that only clin-
ical but not parasitological failures could be detected
beyond the follow-up of day 28. This allowed the detec-
tion of some additional LCF; most of them by day 42 in
the CQ and SP monotherapy groups, while an additional
LCF was detected by day 63 in the SP-AS group. Therefore,
though the 28-day follow-up misses some events, it
remains a fair estimation of the efficacy of a given drug
since it allowed the detection of 91.5% of all LCF (PCR
corrected). However, extending the follow-up to day 42
post-treatment would give a better estimate of the drug
efficacy, as 40% of the few remaining LCF (PCR corrected)
after day 28 were detected before day 42.
The good efficacy of SP-AS was surprising when consider-
ing the high clinical failure rate in the SP alone group
(41.5% at day 90). A three-day treatment with AS is an
incomplete treatment when resistance to the partner drug
is already high. However, good efficacy of the combina-
tion SP-AS, over 90% at day 28, has already been reported
from some African sites with high SP resistance [22-24],
while in others with similar SP resistance, the efficacy of
SP-AS was not as high [25]. Moreover, effectiveness of the
treatment could be as low as 63.4%, when patient's com-
pliance is low, a problem due to the non-availability of a
co-formulated treatment [24]. These results confirm that
in areas where SP total clinical failure is as high as 29.4%
at day 28 or 41.5% at day 90, adding AS to SP improves
considerably the efficacy of the treatment. Such an
improvement cannot be explained by a short follow-up
unable to detect all failures. Indeed, even at day 90, the
clinical failure rate in patients treated with SP-AS was as
low as 2.7%.
The prevalence of the point mutations in the dihydro-
folate reductase (dhfr) and dihydropteroate synthase
(dhps) genes linked to SP treatment failure [5] may be a
useful element to consider when trying explaining the rel-
atively high efficacy in the SP-AS group. The dhfr muta-
tions 108, 51 and 59 have been related to pyrimethamine
resistance [26], whereas the dhps mutations 437 and 540
to sulphadoxine resistance [27,28]. The occurrence of
these mutations may occur in a stepwise fashion, with
selection for mutations in the dhfr gene probably occur-
ring first and the dhps mutations following later [29]. In
Uganda, the presence of the dhps 540 mutations was a
much stronger predictor of clinical treatment failure than
the dhfr 59 mutation [30]. In this study area, the dhps 540
wild-type associated with the dhfr 59 and dhps 437 muta-
tions was the most prevalent haplotype but it was not
associated with SP treatment failure, possibly because of
the lack of mutations in other codons, e.g. 51 in the dhfr
gene. Treatment failure with SP associated to the dhps 437
mutation is lower than that with the dhps 540 mutation
[30] and when AS is associated with SP such risk may be
further reduced [30]. Only three samples carrying the dhps
540 mutation with the dhps 437 wild type were found,
similar to other reports in which the occurrence of the
dhps 540 mutation without the dhps 437 mutation was
uncommon [30]. Therefore, the relatively high efficacy of
SP-AS may be partly explained by the low prevalence of
infections with the dhps  540 mutation. Additional ele-
ments to be considered are the rapid effect of AS on para-
site load [31] and the interaction between treatment and
acquired immunity. Indeed, the reduction of parasitaemia
after treatment with AS is so dramatic that SP, despite high
resistance when given alone, may be able to remove the
remaining parasites, helped also by the patient's acquired
immunity. However, assuming that the dhps mutationsMalaria Journal 2009, 8:37 http://www.malariajournal.com/content/8/1/37
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occur in a stepwise fashion, first the dhps 437 and then the
dhps 540 mutations, a process driven by drug pressure,
and that indeed the double mutant is associated with a
higher risk of failure, the efficacy of SP-AS may rapidly
decrease over time if this treatment or SP alone are com-
monly used.
When considering only the PCR-confirmed recrudes-
cences, only 18.4% of the LPF evolved towards a LCF
within the 28-day follow-up. This proportion is much
lower than that obtained in several trials carried out in
sub-Saharan Africa in which more than 40% of the LPF
cases evolved towards LCF within 28 days post-treatment
[32]. In the study, one additional child experienced a LCF
between day 29 and day 90, increasing the risk of devel-
oping clinical malaria to 21.0% (8/38). This is lower to
what has been reported in Uganda where the risk of devel-
oping symptomatic malaria within 30 days was 50% [33].
Similarly, in Gabon only a small proportion of infected
children remained asymptomatic for five days or more
[34]. However, in the present study, more than half of
these children never developed symptoms, even after a
follow-up of about three months. Such difference may be
explained by the age pattern of the cohort as at the end of
the study the youngest children were at least 24 months
old and the oldest 77 month old. Considering this is an
area of intense and perennial transmission [13,14], the
large majority of children probably had some degree of
acquired immunity that contributed to either delaying the
evolution towards clinical disease or even clearing the
infection [14,35-38].
Conclusion
Combining AS to SP dramatically increased the treatment
efficacy, even when extending the follow-up to day 90
post-treatment, and despite the high percentage of failures
following treatment with SP alone. Such a good perform-
ance may be explained by several factors including the low
prevalence of the dhps 540 mutation, the rapid reduction
of the parasite load by AS and the interaction between
acquired immunity and treatment. In 2004, Benin has
chosen artemether-lumefantrine and amodiaquine-
artesunate as recommended first-line treatments for
uncomplicated malaria. Their deployment in peripheral
health facilities has been slow though now the situation is
gradually improving (A. Nahum, personal communica-
tion). Experiences from several African countries [39-42]
indicate that the deployment of a new drug policy during
the transition period suffers multiple constraints, includ-
ing unavailability of the new treatment(s) due to stock-
outs. Both SP and AS are easily available in Benin and
their combination offers a good alternative whenever the
two recommended anti-malaria treatments are not availa-
ble [43,44].
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